1.0 Introduction

These guidelines are intended for the management of admitted surgical oncology patients with a focus on solid tumor patients, who develop a postoperative fever. Patients are to be removed from this pathway if there is a change in diagnosis.

These guidelines were developed by an interdisciplinary clinical team from SickKids using research evidence, clinical experience and consensus agreement.

These guidelines were developed as a result of evidence obtained from a retrospective chart review of 98 surgical oncology patients. It was found that 74% of oncology patients develop fevers. Of the patients with fever, 14% had documented infections. A diagnosis of neuroblastoma, and surgery length greater than 8 hours were significant predictors of infection (p=0.015/p=0.059). This review highlighted the importance of a prompt physical assessment, and work-up of these patients.

The target users of this guideline are surgeons, oncologists, fellows, residents, and nurses caring for surgical oncology patients.

2.0 Definitions

Fever: Fever is defined as a single oral temperature ≥ 38.3°C or oral temperature ≥ 38°C for 1 hour or more. Oral temperatures are more reliable and are thus preferred. However, when axillary temperatures are the only option, fever is defined as a single axillary temperature of ≥ 37.8°C or axillary temperature ≥ 37.5°C for 1 hour or more.

Postoperative fever: Fevers that develop within 7 days post-surgery

Neutropenia: ANC (Absolute Neutrophil Count) <0.5X 10^9/L

Solid tumors: Neuroblastoma, Osteosarcoma, Ewing's Sarcoma, Wilms’ Tumour, Hepatoblastoma, Germ Cell Tumour, Rhabdomyosarcoma, Soft Tissue Sarcoma, etc.

3.0 Clinical Practice Guideline

3.1 Assessment

3.1.1. Solid Tumour patients who develop fevers after undergoing surgery require an immediate and comprehensive assessment by the surgical team. This assessment must include:

- Physical examination
- CBC, differential
• Blood cultures: from central venous catheters (even if not accessed), or peripheral if no central catheter

3.1.2 Consideration should also be given to obtain\([\text{Grade C}]\):
• Urine cultures (especially in patients catheterized during surgery)
• Wound, drain, other fluid cultures based on clinical status
• Chest x-ray

3.2 Antibiotics

3.2.1. Solid Tumor patients, who have received chemotherapy, may require empiric antibiotic therapy even if they are not neutropenic. Antibiotics should be started promptly in children who are unwell, unstable or have evidence of bacterial infection. A low threshold to start antibiotics should be used even in well appearing children, based on the consideration of factors such as diagnosis, length of surgery, and intensity of pre-surgical chemotherapy. This decision should be made based on clinical status after a physical assessment has been done.\([\text{Grade C}]\)

3.2.2. If empiric antibiotic therapy is warranted (i.e. systemic manifestations such as: hypotension, rigours, sepsis syndrome, decreased urine output, or altered level of consciousness are present\([1,2,3,4,5,6,7,8]\)) please refer to Table 1 in Management of Haematology/Oncology & Haematopoietic Stem Cell Transplant Patients with Fever.

3.3 Consults

3.3.1. The Oncology service must be immediately consulted for all febrile solid tumor patients in the postoperative period and is responsible for assessing the patient as soon as possible.

3.3.2. Other services should be consulted as indicated (i.e. infectious diseases).

4.0 Related Documents


Management of Haematology/Oncology & Haematopoietic Stem Cell Transplant Patients with Fever.

Sepsis Early Management Pathway

5.0 Statement of Evidence

A literature search was completed using Pubmed, using key words: postoperative fever, pediatric, oncology. A systematic review and details of the literature search have been published previously.\(^2\) There were no directly relevant articles regarding pediatric oncology patients specifically in the published literature. The CPG development group and the solid tumour team met on several occasions to discuss the literature and to update these recommendations. This pathway is based on Level C evidence: Expert Opinion.

6.0 References


7.0 Guideline Group and Reviewers

**Guideline Group Membership**

Eleanor Hendershot RN, MN, ACNP, APN Hematology/Oncology
Ann Chang RN, MN, ANPE Hematology/Oncology
Kimberly Colapinto RN, MN, ACNP, APN General Surgery
Lillian Sung MD, Hematology/Oncology
David Malkin MD, Hematology/Oncology
Ted Gerstle MD, General Surgery

**Internal Reviewers**

Jacob Langer MD General Surgery
Jim Whitlock MD Haematology/Oncology

**Revision History:**
Approved by the Haematology/Oncology/BMT/Immunology/Allergy Quality, Utilization and Patient Care Committee on January 14, 2008.
Approved by the Perioperative Surgical Committee: Monday March 3, 2008.

**Attachments:**

[Revision History.docx](#)